On September 4, 2015 Clovis Oncology (NASDAQ:CLVS)reported that rociletinib, the company’s oral targeted covalent (irreversible) mutant-selective inhibitor of epidermal growth factor receptor (EGFR) in development for the treatment of EGFR-mutated, T790M positive non-small cell lung cancer (NSCLC), is the subject of four mini-oral presentations and two poster sessions at the 16th World Conference on Lung Cancer (Press release, Clovis Oncology, SEP 4, 2015, View Source;p=RssLanding&cat=news&id=2085448 [SID:1234507399]). Hosted by the International Association for the Study of Lung Cancer (IASLC), the conference will take place September 6-9, 2015 in Denver.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing updated data from the pivotal TIGER-X trial, analyzing the clinical activity of rociletinib in multiple subsets of patients with advanced EGFR mutant NSCLC, specifically in those with a history of CNS metastases, as well as in patients with T790M negative disease," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "The coming months are shaping up to be a very busy and important time for rociletinib, as we move forward with our pivotal TIGER clinical trial program and prepare for potential product launches in both the United States and Europe."

Mini-Oral Presentations

Rociletinib in NSCLC patients with negative central testing for T790M in TIGER-X (Abstract #951/MINI03.10)

Heather Wakelee, MD, Stanford University Medical Center
Monday, Sept. 7, 4:45-6:15pm MT
Location: Four Seasons Ballroom F1 + F2
Identification of effective drug combinations to prevent or delay resistance to the EGFR mutant selective inhibitor rociletinib (CO-1686) (Abstract #3010/MINI09.04)

Andrew D. Simmons, PhD, Clovis Oncology
Monday, Sept. 7, 4:45-6:15pm MT
Location: Rooms 205 + 207
Dose optimization of rociletinib for EGFR mutated NSCLC (Abstract #967/MINI16.03)

Jonathan W. Goldman, MD, UCLA Health
Tuesday, Sept. 8, 4:45-6:15pm MT
Location: Four Seasons Ballroom F3 + F4
Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement (Abstract #965/MINI16.04)

D. Ross Camidge, MD, PhD, University of Colorado Denver
Tuesday, Sept. 8, 4:45-6:15pm MT
Location: Four Seasons Ballroom F3 + F4
Poster Sessions

Poster P1.01-076 – TIGER-1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer

D. Ross Camidge, MD, PhD, University of Colorado Denver
Monday, Sept. 7, 9:30am-4:45pm MT
Location: Exhibit Hall
Poster P1.01-086 – TIGER-3: A phase 3, open-label, randomized study of rociletinib versus cytotoxic chemotherapy in patients with mutant EGFR non-small cell lung cancer progressing on prior EGFR tyrosine kinase inhibitor therapy and doublet chemotherapy

James Chih-Hsin Yang, National Taiwan University Hospital
Monday, Sept. 7, 9:30am-4:45pm MT
Location: Exhibit Hall
About Rociletinib

Rociletinib is an oral, potent, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) under investigation for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Rociletinib targets the activating mutations of EGFR (L858R and Del19), while also inhibiting the dominant acquired resistance mutation, T790M, which develops in approximately 60 percent of patients treated with first- and second-generation EGFR inhibitors, while sparing wild-type, or "normal" EGFR at anticipated therapeutic doses. Rociletinib was granted Breakthrough Therapy designation by the U.S. FDA in May 2014.